[HTML][HTML] Immune checkpoint inhibitor-associated pneumonitis in non-small cell lung cancer: current understanding in characteristics, diagnosis, and management
Q Zhang, L Tang, Y Zhou, W He, W Li - Frontiers in immunology, 2021 - frontiersin.org
Immunotherapy that includes programmed cell death-1 (PD-1), programmed cell death-
ligand 1 (PD-L1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) inhibitors has …
ligand 1 (PD-L1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) inhibitors has …
Checkpoint inhibitor pneumonitis induced by anti-PD-1/PD-L1 therapy in non-small-cell lung cancer: occurrence and mechanism
J Yin, Y Wu, X Yang, L Gan, J Xue - Frontiers in Immunology, 2022 - frontiersin.org
Immune checkpointty inhibitors (ICIs), particularly those targeting programmed death 1 (PD-
1) and anti-programmed death ligand 1 (PD-L1), enhance the antitumor effect by restoring …
1) and anti-programmed death ligand 1 (PD-L1), enhance the antitumor effect by restoring …
[HTML][HTML] Crossed pathways for radiation-induced and immunotherapy-related lung injury
Z Zhang, J Zhou, V Verma, X Liu, M Wu, J Yu… - Frontiers in …, 2021 - frontiersin.org
Radiation-induced lung injury (RILI) is a form of radiation damage to normal lung tissue
caused by radiotherapy (RT) for thoracic cancers, which is most commonly comprised of …
caused by radiotherapy (RT) for thoracic cancers, which is most commonly comprised of …
IL-35 regulates the function of immune cells in tumor microenvironment
K Liu, A Huang, J Nie, J Tan, S Xing, Y Qu… - Frontiers in …, 2021 - frontiersin.org
Interleukin-35 (IL-35) is a heterodimeric cytokine composed of Epstein-Barr virus-induced
gene 3 (EBI3) and IL-12p35 that has recently been shown to play diverse and important …
gene 3 (EBI3) and IL-12p35 that has recently been shown to play diverse and important …
[HTML][HTML] Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study
Background Immune checkpoint inhibitors (ICIs) have improved survival and are
increasingly used for non-small cell lung cancer. However, use may be limited by immune …
increasingly used for non-small cell lung cancer. However, use may be limited by immune …
Radiation combined with immune checkpoint inhibitors for unresectable locally advanced non-small cell lung cancer: synergistic mechanisms, current state …
L Wu, Z Zhang, M Bai, Y Yan, J Yu, Y Xu - Cell Communication and …, 2023 - Springer
Until the advent of immune checkpoint inhibitors (ICIs), definitive radiotherapy (RT)
concurrently with chemotherapy was recommended for unresectable, locally advanced non …
concurrently with chemotherapy was recommended for unresectable, locally advanced non …
[HTML][HTML] Neutrophil elastase: From mechanisms to therapeutic potential
W Zeng, Y Song, R Wang, R He, T Wang - Journal of Pharmaceutical …, 2023 - Elsevier
Neutrophil elastase (NE), a major protease in the primary granules of neutrophils, is
involved in microbicidal activity. NE is an important factor promoting inflammation, has …
involved in microbicidal activity. NE is an important factor promoting inflammation, has …
ISG15 targets glycosylated PD-L1 and promotes its degradation to enhance antitumor immune effects in lung adenocarcinoma
T Qu, W Zhang, C Yan, D Ren, Y Wang, Y Guo… - Journal of Translational …, 2023 - Springer
Abstract Background Immunocheckpoint inhibitors (ICIs) have been widely used in the
clinical treatment of lung cancer. Although clinical studies and trials have shown that …
clinical treatment of lung cancer. Although clinical studies and trials have shown that …
Inhibitory role of bone marrow mesenchymal stem cells‐derived exosome in non‐small‐cell lung cancer: microRNA‐30b‐5p, EZH2 and PI3K/AKT pathway
T Wu, Q Tian, R Liu, K Xu, S Shi… - Journal of Cellular …, 2023 - Wiley Online Library
Exosomal microRNA (miRNA) exerts potential roles in non‐small‐cell lung cancer (NSCLC).
The current study elucidated the role of miR‐30b‐5p shuttled by bone marrow mesenchymal …
The current study elucidated the role of miR‐30b‐5p shuttled by bone marrow mesenchymal …
Immune checkpoint inhibition in COVID-19: risks and benefits
PS Pezeshki, N Rezaei - Expert Opinion on Biological Therapy, 2021 - Taylor & Francis
Introduction Immune checkpoint inhibition (ICI) is a novel cancer immunotherapy, which is
administered in patients with metastatic, refractory, or relapsed solid cancer types. Since the …
administered in patients with metastatic, refractory, or relapsed solid cancer types. Since the …
